494 related articles for article (PubMed ID: 27091835)
1. Glargine Insulin Use Versus Continuous Regular Insulin in Diabetic Surgical Noncritically Ill Patients Receiving Parenteral Nutrition: Randomized Controlled Study.
Hakeam HA; Mulia HA; Azzam A; Amin T
JPEN J Parenter Enteral Nutr; 2017 Sep; 41(7):1110-1118. PubMed ID: 27091835
[TBL] [Abstract][Full Text] [Related]
2. Glycemic Control in Adult Surgical Patients Receiving Regular Insulin Added to Parenteral Nutrition vs Insulin Glargine: A Retrospective Chart Review.
Truong S; Park A; Kamalay S; Hung N; Meyer JG; Nguyen N; Momenzadeh A
Nutr Clin Pract; 2019 Oct; 34(5):775-782. PubMed ID: 30693980
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of regular versus glargine insulin in stable critical care patients receiving parenteral nutrition: a randomized controlled trial.
Oghazian MB; Javadi MR; Radfar M; Torkamandi H; Sadeghi M; Hayatshahi A; Gholami K
Pharmacotherapy; 2015 Feb; 35(2):148-57. PubMed ID: 25689245
[TBL] [Abstract][Full Text] [Related]
4. Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease.
Ruiz de Adana MS; Colomo N; Maldonado-Araque C; Fontalba MI; Linares F; García-Torres F; Fernández R; Bautista C; Olveira G; de la Cruz JL; Rojo-Martínez G; Valdés S
Diabetes Res Clin Pract; 2015 Nov; 110(2):158-65. PubMed ID: 26474657
[TBL] [Abstract][Full Text] [Related]
5. Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy.
Li FF; Zhang WL; Liu BL; Zhang DF; Chen W; Yuan L; Chen MY; Zhai XF; Wu JD; Su XF; Ye L; Cao HY; Ma JH
Sci Rep; 2018 Apr; 8(1):5888. PubMed ID: 29651052
[TBL] [Abstract][Full Text] [Related]
6. Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes.
Demma LJ; Carlson KT; Duggan EW; Morrow JG; Umpierrez G
J Clin Anesth; 2017 Feb; 36():184-188. PubMed ID: 28183563
[TBL] [Abstract][Full Text] [Related]
7. Regular insulin added to total parenteral nutrition vs subcutaneous glargine in non-critically ill diabetic inpatients, a multicenter randomized clinical trial: INSUPAR trial.
Olveira G; Abuín J; López R; Herranz S; García-Almeida JM; García-Malpartida K; Ferrer M; Cancer E; Luengo-Pérez LM; Álvarez J; Aragón C; Ocón MJ; García-Manzanares Á; Bretón I; Serrano-Aguayo P; Pérez-Ferre N; López-Gómez JJ; Olivares J; Arraiza C; Tejera C; Martín JD; García S; Abad ÁL; Alhambra MR; Zugasti A; Parra J; Torrejón S; Tapia MJ
Clin Nutr; 2020 Feb; 39(2):388-394. PubMed ID: 30930133
[TBL] [Abstract][Full Text] [Related]
8. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
Takeishi S; Tsuboi H; Takekoshi S
Endocr J; 2017 Oct; 64(10):995-1005. PubMed ID: 28824042
[TBL] [Abstract][Full Text] [Related]
9. Insulin glargine in patients with severe hepato-gastroenterology diseases and hyperglycemia receiving parenteral nutrition.
Fatati G; Mirri E; Palazzi M; Vendetti AL; Pierotti F; Weber P; Mattei R; Parillo M; Coaccioli S; Puxeddu A
Clin Ter; 2006; 157(6):511-5. PubMed ID: 17228850
[TBL] [Abstract][Full Text] [Related]
10. Hypoglycemia in noncritically ill patients receiving total parenteral nutrition: a multicenter study. (Study group on the problem of hyperglycemia in parenteral nutrition; Nutrition area of the Spanish Society of Endocrinology and Nutrition).
Olveira G; Tapia MJ; Ocón J; Cabrejas-Gómez C; Ballesteros-Pomar MD; Vidal-Casariego A; Arraiza-Irigoyen C; Olivares J; Conde-García MC; García-Manzanares Á; Botella-Romero F; Quílez-Toboso RP; Matía P; Rubio MÁ; Chicharro L; Burgos R; Pujante P; Ferrer M; Zugasti A; Petrina E; Manjón L; Diéguez M; Carrera MJ; Vila-Bundo A; Urgelés JR; Aragón-Valera C; Sánchez-Vilar O; Bretón I; García-Peris P; Muñoz-Garach A; Márquez E; Del Olmo D; Pereira JL; Tous MC
Nutrition; 2015 Jan; 31(1):58-63. PubMed ID: 25441588
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
[TBL] [Abstract][Full Text] [Related]
12. An insulin protocol for management of hyperglycemia in patients receiving parenteral nutrition is superior to ad hoc management.
Jakoby MG; Nannapaneni N
JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2):183-8. PubMed ID: 21825091
[TBL] [Abstract][Full Text] [Related]
13. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).
Terauchi Y; Koyama M; Cheng X; Sumi M; Riddle MC; Bolli GB; Hirose T;
Diabetes Metab; 2017 Oct; 43(5):446-452. PubMed ID: 28433560
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial.
Pasquel FJ; Lansang MC; Khowaja A; Urrutia MA; Cardona S; Albury B; Galindo RJ; Fayfman M; Davis G; Migdal A; Vellanki P; Peng L; Umpierrez GE
Diabetes Care; 2020 Jun; 43(6):1242-1248. PubMed ID: 32273271
[TBL] [Abstract][Full Text] [Related]
15. RISK FACTORS FOR HYPOGLYCEMIA IN INPATIENTS WITH TOTAL PARENTERAL NUTRITION AND TYPE 2 DIABETES: A POST HOC ANALYSIS OF THE INSUPAR STUDY.
Olveira G; Abuín J; López R; Herranz S; García-Almeida JM; García-Malpartida K; Ferrer M; Cancer E; Luengo-Pérez LM; Álvarez J; Aragón C; Ocón MJ; García-Manzanares Á; Bretón I; Serrano-Aguayo P; Pérez-Ferre N; López-Gómez JJ; Olivares J; Arraiza C; Tejera C; Martín JD; Urioste-Fondo A; Abad ÁL; Alhambra MR; Zugasti A; Parra J; Torrejón S; Tapia MJ
Endocr Pract; 2020 Jun; 26(6):604-611. PubMed ID: 32160049
[No Abstract] [Full Text] [Related]
16. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery.
Yeldandi RR; Lurie A; Baldwin D
Diabetes Technol Ther; 2006 Dec; 8(6):609-16. PubMed ID: 17109592
[TBL] [Abstract][Full Text] [Related]
17. Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study.
Ilany J; Bhandari H; Nabriski D; Toledano Y; Konvalina N; Cohen O
Diabetes Obes Metab; 2018 May; 20(5):1186-1192. PubMed ID: 29316176
[TBL] [Abstract][Full Text] [Related]
18. Reducing Blood Glucose Testing Is Safe in Patients Receiving Parenteral Nutrition.
Ratliff A; Nishnick A; DeChicco R; Lopez R
Nutr Clin Pract; 2018 Dec; 33(6):872-878. PubMed ID: 29532507
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
